知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

194 条记录 (耗时 0.045 秒)

    C13-HYDROXY DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF
    43.
    发明申请
    C13-HYDROXY DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF 有权
    油酸C13-羟基衍生物及其使用方法

    公开(公告)号：US20140088188A1

    公开(公告)日：2014-03-27

    申请号：US14023180

    申请日：2013-09-10

    申请人： REATA PHARMACEUTICALS, INC.

    发明人： Xin JIANG ,  Christopher F. BENDER ,  Melean VISNICK

    IPC分类号： C07C255/47 ,  C07D307/00

    CPC分类号： C07C255/47 ,  C07D307/00 ,  C07J63/008

    摘要： Disclosed herein are novel C13-hydroxy derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.

    摘要翻译： 本文公开了齐墩果酸的新C13-羟基衍生物，包括下式的那些：其中变量在本文中定义。 还提供了包含这些化合物的药物组合物，试剂盒和制品。 还提供了可用于制备化合物的方法和中间体，以及使用该化合物的方法，例如抗氧化剂炎症调节剂及其组合物。

    MONOMER HAVING ELECTRON-WITHDRAWING SUBSTITUENT AND LACTONE SKELETON, POLYMERIC COMPOUND, AND PHOTORESIST COMPOSITION
    48.
    发明申请
    MONOMER HAVING ELECTRON-WITHDRAWING SUBSTITUENT AND LACTONE SKELETON, POLYMERIC COMPOUND, AND PHOTORESIST COMPOSITION 有权
    具有电子取代取代基和LACTONE SKELETON，聚合物和光催化剂组合物的单体

    公开(公告)号：US20100297555A1

    公开(公告)日：2010-11-25

    申请号：US12863924

    申请日：2009-02-03

    申请人： Hiroshi Koyama ,  Kyuhei Kitao ,  Akira Eguchi

    发明人： Hiroshi Koyama ,  Kyuhei Kitao ,  Akira Eguchi

    IPC分类号： G03F7/20 ,  C07D307/77 ,  C08F24/00 ,  G03F7/004

    CPC分类号： C07D307/93 ,  C07D307/00 ,  C08F220/18 ,  C08F220/28 ,  G03F7/0397

    摘要： Disclosed is a monomer having an electron-withdrawing substituent and a lactone skeleton, represented by following Formula (1), wherein Ra represents, e.g., a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; R1 represents, e.g., a halogen atom or an alkyl or haloalkyl group having 1 to 6 carbon atoms; “A” represents an alkylene group having 1 to 6 carbon atoms, oxygen atom, sulfur atom, or nonbonding; “m” denotes an integer of 0 to 8; Xs each represent an electron-withdrawing substituent; “n” denotes an integer of 1 to 9; and Y represents a bivalent organic group having 1 to 6 carbon atoms.The monomer is useful typically as a monomer component typically for a highly functional polymer, because, when the monomer is applied typically to a resist resin, the resin is satisfactory stable and resistant typically to chemicals, is highly soluble in organic solvents, and has improved hydrolyzability and/or solubility in water after hydrolysis.

    摘要翻译： 公开了具有吸电子取代基和内酯骨架的单体，其由下式（1）表示，其中Ra表示例如氢原子或具有1至6个碳原子的烷基; R1表示例如卤素原子或碳原子数为1〜6的烷基或卤代烷基; “A”表示碳原子数1〜6的亚烷基，氧原子，硫原子，或非键合物。 “m”表示0〜8的整数， Xs各自表示吸电子取代基; “n”表示1〜9的整数， Y表示碳原子数为1〜6的2价有机基团。 单体通常用作高官能聚合物的单体组分，因为当单体通常用于抗蚀剂树脂时，树脂是令人满意的稳定和耐化学物质，高度可溶于有机溶剂，并改善了 水解后水解性和/或水溶性。

    Chiral 1,8-Diarylnaphthalenes, Methods of Making Them, and Their Use as Sensors
    49.
    发明申请
    Chiral 1,8-Diarylnaphthalenes, Methods of Making Them, and Their Use as Sensors 有权
    手性1,8-二芳基萘，其制备方法及其用作传感器

    公开(公告)号：US20070276140A1

    公开(公告)日：2007-11-29

    申请号：US10576567

    申请日：2004-11-01

    申请人： Christian Wolf ,  Xuefeng Mei

    发明人： Christian Wolf ,  Xuefeng Mei

    IPC分类号： C07D219/02

    CPC分类号： C07D213/06 ,  C07D213/89 ,  C07D219/02 ,  C07D221/18 ,  C07D307/00 ,  G01N33/52

    摘要： One aspect of the invention relates to 1,8-diarylnaphthalene compounds. In certain embodiments, a compound of the invention is an N-oxide of a 1,8-diarylnaphthalene. In certain embodiments, the aryl group is an optionally substituted acridyl group. In certain embodiments, a compound of the invention is a single steroisomer. In certain embodiments, a compound of the invention is a single enantiomer. Another aspect of the present invention relates to a method of detecting the presence of an analyte in a sample by monitoring the fluorescence of a compound of the invention in a sample. In certain embodiments, the analyte is a metal ion. Another aspect of the present invention relates to a method of determining the enantiomeric purity of an analyte by monitoring the fluorescence of a compound of the invention in the presence of the analyte. In certain embodiments, the analyte is a compound that is capable of hydrogen bonding.

    摘要翻译： 本发明的一个方面涉及1,8-二芳基萘化合物。 在某些实施方案中，本发明的化合物是1,8-二芳基萘的N-氧化物。 在某些实施方案中，芳基是任选取代的吖啶基。 在某些实施方案中，本发明的化合物是单一的立体异构体。 在某些实施方案中，本发明的化合物是单一的对映异构体。 本发明的另一方面涉及通过监测样品中本发明化合物的荧光来检测样品中分析物的存在的方法。 在某些实施方案中，分析物是金属离子。 本发明的另一方面涉及通过在分析物的存在下监测本发明化合物的荧光来测定分析物的对映体纯度的方法。 在某些实施方案中，分析物是能够氢键合的化合物。

    Thromboxane ligands without blood clotting side effects
    50.
    发明授权
    Thromboxane ligands without blood clotting side effects 失效
    血凝素配体无凝血副作用

    公开(公告)号：US06818779B2

    公开(公告)日：2004-11-16

    申请号：US10213190

    申请日：2002-08-05

    申请人： Robert M. Burk ,  Achim H-P Krauss ,  David F. Woodward

    发明人： Robert M. Burk ,  Achim H-P Krauss ,  David F. Woodward

    IPC分类号： C07D30700

    CPC分类号： C07D307/00 ,  A61K31/558 ,  C07D319/08 ,  C07D493/08

    摘要： A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises administering to a mammal suffering therefrom a therapeutically effective amount of a thromboxane ligand which is a compound formula I, wherein Y is (CH2)x; Z is selected from the group consisting of x is an integer of 1 or 2; n is 0 or 1; R2 is hydrogen or an alkyl radical of from 1 to 4 carbons; A is an alkylene or alkenylene radical having from two to seven carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups or said alkylene or alkenylene may have one or more enchained oxa or imino radicals; B is a methyl radical or a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals wherein the heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur atoms, or substituted derivatives of said methyl, cycloalkyl or aryl radicals wherein said substituent is selected from the group consisting of halo, nitro, amino, thiol, hydroxy, alkyloxy and alkylcarboxy; and X is selected from the group consisting of nitro, cyano, —COOR, —CH2OR1, —C(O)N(R1)2, —CH2N(R1)2—CH═N—OH and —CH2SR1 radicals wherein R is a C1 to C10 alkyl, phenyl or benzyl and R1 is R or hydrogen; or a pharmaceutically acceptable salt thereof.

    摘要翻译： 一种治疗眼低血压，高血压，出血，心肌缺血，心绞痛，冠状动脉收缩，蛛网膜下腔出血后脑血管收缩，脑出血和哮喘的方法，其包括向患有其的哺乳动物施用治疗有效量的作为化合物的血栓烷配体 式I，其中Y是（CH 2）x; Z选自x为1或2的整数; n为0或1; R2是氢或1至4个碳的烷基; A是具有2-7个碳原子的亚烷基或亚烯基，该基团可以被一个或多个羟基，氧代，烷氧基或烷基羧基取代，或者所述亚烷基或亚烯基可以具有一个或多个链烯氧基或亚氨基; B是具有3至7个碳原子的甲基或环烷基，或选自烃基芳基和杂芳基的芳基，其中杂原子选自氮，氧和硫原子， 或所述甲基，环烷基或芳基的取代衍生物，其中所述取代基选自卤素，硝基，氨基，硫醇，羟基，烷氧基和烷基羧基; 并且X选自硝基，氰基，-COOR，-CH 2 OR 1，-C（O）N（R 1）2，-CH 2 N（R 1）2 -CH = N-OH和-CH 2 S R 1基团，其中R为 C1至C10烷基，苯基或苄基，R1为R或氢; 或其药学上可接受的盐。